Rethinking 3D modelling for a world that generates too much, too quickly.
Updated
January 8, 2026 6:32 PM
A hologram in the franchise Star Wars, in Walt Disney World Resort, Orlando. PHOTO: UNSPLASH
MicroCloud Hologram Inc. (NASDAQ: HOLO), a technology service provider recognized for its holography and imaging systems, is now expanding into a more advanced realm: a quantum-driven 3D intelligent model. The goal is to generate detailed 3D models and images with far less manual effort — a need that has only grown as industries flood the world with more visual data every year.
The concept is straightforward, even if the technology behind it isn’t. Traditional 3D modeling workflows are slow, fragmented and depend on large teams to clean datasets, train models, adjust parameters and fine-tune every output. HOLO is trying to close that gap by combining quantum computing with AI-powered 3D modeling, enabling the system to process massive datasets quickly and automatically produce high-precision 3D assets with much less human involvement.
To achieve this, the company developed a distributed architecture comprising of several specialized subsystems. One subsystem collects and cleans raw visual data from different sources. Another uses quantum deep learning to understand patterns in that data. A third converts the trained model into ready-to-use 3D assets based on user inputs. Additional modules manage visualization, secure data storage and system-wide protection — all supported by quantum-level encryption. Each subsystem runs in its own container and communicates through encrypted interfaces, allowing flexible upgrades and scaling without disrupting the entire system.
Why this matters: Industries ranging from gaming and film to manufacturing, simulation and digital twins are rapidly increasing their reliance on 3D content. The real bottleneck isn’t creativity — it’s time. Producing accurate, high-quality 3D assets still requires a huge amount of manual processing. HOLO’s approach attempts to lighten that workload by utilizing quantum tools to speed up data processing, model training, generation and scaling, while keeping user data secure.
According to the company, the system’s biggest advantages include its ability to handle massive datasets more efficiently, generate precise 3D models with fewer manual steps, and scale easily thanks to its modular, quantum-optimized design. Whether quantum computing will become a mainstream part of 3D production remains an open question. Still, the model shows how companies are beginning to rethink traditional 3D workflows as demand for high-quality digital content continues to surge.
Keep Reading
How a Korean biotech startup is using AI to move drug discovery from trial-and-error to precision design
A close up of a protein structure model. PHOTO: UNSPLASH
For decades, drug discovery has relied on trial and error, with scientists testing thousands of molecules to find one that works. Galux, a South Korean biotech startup, is changing that by using AI to design proteins from scratch. This method, called “de novo” design, makes it possible to build precise new therapies instead of searching through existing ones.
The company recently announced a US$29 million Series B funding round, bringing its total capital to US$47 million.This significant investment attracted a substantial roster of institutional backers, including the Korea Development Bank (KDB), Yuanta Investment, SL Investment and NCORE Ventures. These firms joined existing investors such as InterVest, DAYLI Partners and PATHWAY Investment, as well as new participants including SneakPeek Investments, Korea Investment & Securities and Mirae Asset Securities.
At the core of the company’s work is a platform called GaluxDesign. Unlike many AI tools that only predict how existing proteins fold, this system uses deep learning and physics to create entirely new therapeutic antibodies. This “from scratch” approach lets the team go after so-called “undruggable” proteins. These are targets that traditional small-molecule drugs can’t reach because they lack clear binding pockets. By designing proteins to fit these complex shapes, Galux aims to unlock treatments that have stayed out of reach for decades. And that’s exactly why investors are paying attention.
The pharmaceutical industry is actively looking for faster and more efficient ways to develop new drugs, and Galux is built for exactly that. The company connects its AI platform directly to its own wet lab, where designs can be tested in real time. Each result feeds straight back into the system, sharpening the next round of models. This continuous loop speeds up discovery and improves precision at every step. It’s also why partners like Celltrion, LG Chem and Boehringer Ingelheim are already working with Galux.
Galux is no longer just trying to make drugs that stick to a target. The company now wants its AI to design medicines that actually work in the body and can be made at scale. In simple terms, a drug has to do more than bind to a disease—it must be stable, safe and strong enough to change how the illness behaves. Galux is moving into tougher targets such as ion channels and GPCRs. These play key roles in heart function and sensory signals. Ultimately, the goal is to show that AI-driven design can turn complex biology into real treatments. And instead of hunting blindly for a solution, the team is building exactly what they need.